RONKONKOMA, N.Y., Dec. 04, 2025 (GLOBE NEWSWIRE) -- SUNation Energy Inc. (Nasdaq: SUNE) (“SUNation” or the “Company”), a leading provider of sustainable solar energy and backup power to households, businesses, municipalities, and for servicing existing systems, today announced that it will make a final cash distribution to holders of non-transferable Contingent Value Rights (“CVRs”) of $0.12 per CVR. The result of this final payment is that there will remain no future payments due or owing by the Company. A ...

Core Viewpoint - Quantum BioPharma Ltd. announces the expiration of 53,147 warrants and reiterates the record date for the distribution of contingent value rights (CVRs) to shareholders, linked to ongoing litigation against financial institutions for alleged stock price manipulation [1][2][3]. Group 1: Warrants Expiration - The company has expired 53,147 warrants, which were part of a previous financing completed on October 20, 2020, and represents the last tranche issued to hedge funds and investment funds [1]. - The original number of warrants issued was 3,454,543 before a reverse stock split of 65 to 1 [1]. Group 2: Contingent Value Rights (CVRs) - The record date for the distribution of CVRs is set for October 27, 2025, on a one-for-one basis for holders of Class B Subordinate Voting Shares [2]. - Each CVR will entitle holders to a pro rata portion of a minimum of 10% and up to 50% of the net proceeds from the company's legal action against CIBC World Markets, RBC Dominion Securities, and others, which seeks damages exceeding USD $700 million [3][4]. - Payments under the CVRs will only occur if the company receives net proceeds from the litigation, and there is no guarantee that any proceeds will be received [5][8]. Group 3: Company Overview - Quantum BioPharma is focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, with drug candidates at various stages of development [6]. - The company’s lead compound, Lucid-MS, is designed to prevent and reverse myelin degradation, a key mechanism in multiple sclerosis, and is currently in preclinical models [6]. - Quantum BioPharma retains a 20.10% ownership stake in Unbuzzd Wellness Inc., which is involved in the development of health products, and has a royalty agreement that provides 7% of sales until total payments reach $250 million, after which the royalty rate drops to 3% [6].